BIOREGENX, INC. (BRGX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 400K 800K 1.2M Q1 '22: 7.7K Q2 '22: 14.3K Q3 '22: 11.3K Q4 '22: 8.9K Q1 '23: 1.1M Q2 '23: 863.3K Q3 '23: 794.5K Q4 '23: 678K Q1 '24: 549.5K Q2 '24: 734K Q3 '24: 596K Q4 '24: 460.5K Q1 '25: 515.1K Q2 '25: 446K Q3 '25: 507.8K Q4 '25: 385.6K Q1 '26: 426.2K Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Gross Profit Quarterly

0 300K 600K 900K Q1 '23: 763.9K Q2 '23: 598.3K Q3 '23: 571.2K Q4 '23: 378K Q1 '24: 384.2K Q2 '24: 469.9K Q3 '24: 481.6K Q4 '24: 322.7K Q1 '25: 406K Q2 '25: 352.5K Q3 '25: 426.4K Q4 '25: 318.8K Q1 '26: 348.3K Q1 '23 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26

Operating Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q1 '22: -37.3K Q2 '22: -33.3K Q3 '22: -2.2K Q4 '22: -5.5K Q1 '23: -184.1K Q2 '23: -544.6K Q3 '23: -2.5M Q4 '23: -211.6K Q1 '24: -3.1M Q2 '24: -1M Q3 '24: -327.3K Q4 '24: -18.3M Q1 '25: -192.6K Q2 '25: -107.3K Q3 '25: -8.5K Q4 '25: -935.7K Q1 '26: -49.8K Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Net Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q1 '22: -37.3K Q2 '22: -33.3K Q3 '22: -2.2K Q4 '22: -5.5K Q1 '23: -229.8K Q2 '23: -594.5K Q3 '23: -2.5M Q4 '23: -256.7K Q1 '24: -3.2M Q2 '24: -1.1M Q3 '24: -394.9K Q4 '24: -18.4M Q1 '25: -266.9K Q2 '25: -178.3K Q3 '25: -80.6K Q4 '25: -1M Q1 '26: -26.4K Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Cost of Revenue Quarterly

0 150K 300K 450K Q1 '23: 311.7K Q2 '23: 265K Q3 '23: 223.3K Q4 '23: 300K Q1 '24: 165.4K Q2 '24: 264.2K Q3 '24: 114.4K Q4 '24: 137.8K Q1 '25: 109.1K Q2 '25: 93.5K Q3 '25: 81.4K Q4 '25: 66.9K Q1 '26: 77.9K Q1 '23 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26

Operating Cash Flow Quarterly

-750K -500K -250K 0 250K 500K 750K Q1 '22: -20.9K Q2 '22: -33.1K Q3 '22: -6.3K Q4 '22: -4.4K Q1 '23: -336.8K Q2 '23: -649.2K Q3 '23: -283.5K Q4 '23: -245.6K Q1 '24: -104.2K Q2 '24: -177.3K Q3 '24: -31.2K Q4 '24: -11.4K Q1 '25: 37.7K Q2 '25: 3.2K Q3 '25: -71.6K Q4 '25: 69.6K Q1 '26: 26.6K Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Free Cash Flow Quarterly

-750K -500K -250K 0 250K 500K 750K Q1 '23: -336.8K Q2 '23: -649.2K Q3 '23: -283.5K Q4 '23: -245.6K Q1 '24: -293.6K Q2 '24: -177.3K Q3 '24: -31.2K Q4 '24: -11.4K Q1 '25: 37.7K Q2 '25: 3.2K Q3 '25: -77.6K Q4 '25: 66.6K Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 350M 700M 1.1B Q1 '22: 269.7M Q2 '22: 269.7M Q3 '22: 269.7M Q1 '23: 619M Q2 '23: 764.3M Q3 '23: 621.9M Q1 '24: 767.6M Q2 '24: 956.5M Q3 '24: 956.5M Q1 '25: 957M Q2 '25: 959.2M Q3 '25: 960.9M Q1 '26: 969.2M Q1 '22 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.02 -0.01 -0.01 0.00 0.01 0.01 0.02 Q4 '22: 0.00 Q1 '23: 0.00 Q2 '23: 0.00 Q3 '23: 0.00 Q4 '23: 0.00 Q1 '24: 0.00 Q2 '24: 0.00 Q3 '24: 0.00 Q4 '24: -0.02 Q1 '25: -0.02 Q2 '25: -0.02 Q3 '25: -0.02 Q4 '25: 0.00 Q1 '26: 0.00 Q1 '23 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.